Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Retained Earnings (2016 - 2025)

Zevra Therapeutics' Retained Earnings history spans 11 years, with the latest figure at -$764000.0 for Q4 2025.

  • For Q4 2025, Retained Earnings rose 99.85% year-over-year to -$764000.0; the TTM value through Dec 2025 reached -$764000.0, up 99.85%, while the annual FY2025 figure was -$764000.0, 99.85% up from the prior year.
  • Retained Earnings reached -$764000.0 in Q4 2025 per ZVRA's latest filing, up from -$2.4 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $141000.0 in Q1 2024 to a low of -$505.3 million in Q4 2024.
  • Average Retained Earnings over 5 years is -$256.5 million, with a median of -$284.2 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: skyrocketed 100.04% in 2024, then tumbled 158.16% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$267.0 million in 2021, then crashed by 32.47% to -$353.7 million in 2022, then decreased by 13.02% to -$399.8 million in 2023, then decreased by 26.39% to -$505.3 million in 2024, then skyrocketed by 99.85% to -$764000.0 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Retained Earnings are -$764000.0 (Q4 2025), -$2.4 million (Q3 2025), and -$2.4 million (Q2 2025).